Incidence, risk factors, and pathogenesis of second malignancies in patients with non-Hodgkin lymphoma.
Most Non-Hodgkin's Lymphoma patients will survive their diagnosis. High dose chemotherapy and autologous stem cell transplantation, and radiation therapy have all been implicated as risk factors to secondary cancer development. Herein, we will review the molecular biology, examine the epidemiologic findings, discuss the impact of both chemotherapy and radiotherapy, and focus on the special populations of pediatrics and high dose chemotherapy and autologous stem cell transplantation with regard to secondary cancer development.
Tward
Jonathan
J
Huntsman Cancer Hospital, University of Utah, UT 84112-5560, USA. Jonathan.Tward@hci.utah.edu
Glenn
Martha
M
Pulsipher
Michael
M
Barnette
Phillip
P
Gaffney
David
D
D000970:Antineoplastic Agents / Q000009:adverse effects; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D015994:Incidence; D008228:Lymphoma, Non-Hodgkin / Q000473:pathology* / Q000628:therapy; D016609:Neoplasms, Second Primary / Q000453:epidemiology* / Q000209:etiology*; D011878:Radiotherapy / Q000009:adverse effects; D012307:Risk Factors
D000970:Antineoplastic Agents